Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Point-of-Care Diagnostics, Global Health & Biosensors 2020

Chong Ahn's Biography



Chong Ahn, Distinguished University Research Professor, Mitchell P. Kartalia Chair Professor of BioMEMS, University of Cincinnati

Dr Ahn is Distinguished University Research Professor and Mitchell P. Kartalia Endowed Chair Professor of BioMEMS in the Department of Electrical Engineering and Computer Science at the University of Cincinnati. He is currently Director of the Engineering Research Center (ERC) Clean Room and Ohio Center for Microfluidic Innovation (OCMI) at the University of Cincinnati. He has been recognized internationally as one of the pioneers in the Biosensors, BioMEMS, Microfluidics, Lab-on-a-Chips, and Point-of-Care Testing (POCT) clinical diagnostic fields. His research interests include the design, simulation, fabrication and characterization of BioMEMS devices, microfluidic device and systems, biosensors and biochips, lab-on-a-chips, in vitro diagnostics (IVD), and point-of-care testing clinical diagnostics or neurosurgical monitoring. He has published over ~350 journal and peer-reviewed conference proceeding papers, and chaired numerous international conferences and steering committees. He was invited as a plenary or keynote speaker from the prestigious international conferences such as uTAS, Eurosensors, APCOT, or IEEE IEDM. He served as one of the Scientific Advisory Board members of the Bill & Melinda Gates Foundation on microfluidics and point-of-care testing diagnostics in 2016.

He has 12 issued US patents. He was the founder of Siloam Biosciences Inc. (which was acquired by Mico BioMed Inc.) in Cincinnati, Ohio, USA. He was the awardees of the University of Cincinnati’s Emerging Entrepreneur Award (2009) and Established Entrepreneur Award (2011). He received Alice Hamilton Award for Excellence in Occupational Safety and Health Research from CDC-NIOSH in 2020, and received the Best Journal Paper Award of the IEEE Sensors Journal in 2009. He currently serve as an Editor of the IEEE/ASME Journal of Microelectromechanical Systems (JMEMS), Editorial Boards of Micro and Nano Systems Letters and Biochip Journal, Editorial Advisory Board of the Journal of Microfluidics and Nanofluidics, and previously served as the Editorial Boards of the Journal of Micromechanics and Microengineering (JMM), IEEE Sensors Journal, and Small.

Chong Ahn Image

Immunodiagnostic Point-of-Care Testing (POCT) for Rapid Serological Tests of COVID-19 Exposure and Immunity

Wednesday, 30 September 2020 at 09:30

Add to Calendar ▼2020-09-30 09:30:002020-09-30 10:30:00Europe/LondonImmunodiagnostic Point-of-Care Testing (POCT) for Rapid Serological Tests of COVID-19 Exposure and ImmunityPoint-of-Care Diagnostics, Global Health and Biosensors 2020 in Virtual ConferenceVirtual ConferenceSELECTBIOenquiries@selectbiosciences.com

A new compact immunodiagnostic point-of-care testing (POCT) analyzer which can rapidly (within 10-15 minutes) and accurately detect anti-SARS-COV-2 IgG and IgM antibodies has been explored and developed, in combination with a neutralization assay which measures neutralizing antibodies to SARS-CoV-2, with the goal of linking serological diagnostics to immune status of infected individuals.

The compact POCT analyzer platform with a new multiplex microchannel-based capillary flow assay (MCFA) lab chip can perform a rapid, real time measurement of anti-SARS-COV-2 IgM and IgG in whole blood for determining COVID-19 exposure and immunity. The POCT platform consists of (a) a multiplex polymer lab-on-a-chip (LOC) that can successfully integrate multiple features of sandwich ELISA and lateral flow tests to implement MCFA using on-chip dried reagents and (b) a portable compact fluorescent analyzer to simultaneously detect multiple targets from the multiplexing immunoassay LOC.  In addition, the use of a monoclonal antibody specific for the receptor binding domain (RBD) of the S-protein would enable the utilization of the MCFA device for a competitive assay to determine the presence of neutralizing antibody in the patient sample, leading to an ideal POCT that not only detects COVID-19 exposure but can also confer immune status.

This serological diagnostics in a compact POCT analyzer platform will provide a new paradigm for rapid and cost-effective diagnosis of rapidly-transmitting diseases like COVID-19.


Add to Calendar ▼2020-09-28 00:00:002020-09-30 00:00:00Europe/LondonPoint-of-Care Diagnostics, Global Health and Biosensors 2020Point-of-Care Diagnostics, Global Health and Biosensors 2020 in Virtual ConferenceVirtual ConferenceSELECTBIOenquiries@selectbiosciences.com